Combination treatment with meropenem plus levofloxacin is synergistic against pseudomonas aeruginosa infection in a murine model of Pneumonia

Journal of Infectious Diseases

Volumn 211, Issue 8, 2015, Pages 1326-1333

  Louie, Arnold ^a   Liu, Weiguo ^a   Vanguilder, Michael ^b   Neely, Michael N ^b   Schumitzky, Alan ^b   Jelliffe, Roger ^b   Fikes, Steven ^a   Kurhanewicz, Stephanie ^a   Robbins, Nichole ^a   Brown, David ^a   Baluya, Dodge ^a   Drusano, George L ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

levofloxacin; Mathematical Modeling; meropenem; Pseudomonas aeruginosa; synergy

Indexed keywords

LEVOFLOXACIN; MEROPENEM; ANTIINFECTIVE AGENT; THIENAMYCIN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG PENETRATION; DRUG POTENTIATION; DRUG RESPONSE; FEMALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS PNEUMONIA; ANIMAL; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PNEUMONIA; PROCEDURES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

ANIMALS; ANTI-BACTERIAL AGENTS; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; LEVOFLOXACIN; MICE; MICROBIAL SENSITIVITY TESTS; PNEUMONIA; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; THIENAMYCINS;

EID: 84926642966     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu603     Document Type: Article

References (15)

1. Louie A, Grasso C, Bahniuk N, et al. The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeru-ginosa kill rate and resistance suppression. Antimicrob Agents Chemo-ther 2010; 54:2646-54.
2. Drusano GL, Liu W, Fikes S, et al. Interaction of drug-and granulocyte-mediated killing of Pseudomonas aeruginosa in a murine pneumonia model. J Infect Dis 2014; 210:1319-24.
3. Luyt C-E, Aubry A, Lu Q, et al. Imipenem, meropenem or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia. Antimicrob Agents Chemother 2014; 58:1372-80.
4. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 9th ed. M07-A9. Wayne, PA: Clinical and Laboratory Standards Institute, 2012.
5. Drusano GL, Vanscoy B, Liu W, Fikes S, Brown D, Louie A. Saturability of granulocyte kill of Pseudomonas aeruginosa in a murine model of pneumonia. Antimicrob Agents Chemother 2011; 55:2693-5.
6. Louie A, Fregeau C, Liu W, Kulawy R, Drusano GL. Pharmacodyna-mics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: determination of epithelial lining fluid (ELF) targets. Antimicrob Agents Chemother 2009; 53:3325-30.
7. Drusano GL, Lodise TP, Melnick D, et al. Meropenem penetration into epithelial lining fluid in mice and men and delineation of exposure targets. Antimicrob Agents Chemother 2011; 55:3406-12.
8. Leary R, Jelliffe R, Schumitzky A, Van Guilder M. An adaptive grid non-parametric approach to pharmacokinetic and dynamic (PK/PD) models. In: Proceedings of the 14th IEEE Symposium on Computer-Based Medical Systems. Bethesda, MD: IEEE Computer Society, 2001: 389-394.
9. Drusano GL, Neely M, Van Guilder M, et al. Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis. PLoS One 2014; 9:e101311.
10. D'Argenio DZ, Schumitzky A, Wang X. ADAPT 5 User's Guide: Phar-macokinetic/Pharmacodynamic Systems Analysis Software. Los Angeles: Biomedical Simulations Resource, 2009.
11. Neely MN, van Guilder MG, Yamada WM, Schumitzk A, Jelliffe RW. Accurate detection of outliers and subpopulations with pmetrics, a non-parametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit 2012; 34: 467-76.
12. Lodise TP, Sörgel F, Mason B, Melnick D, Kinzig M, Drusano GL. Penetration of meropenem into epithelial lining fluid in intubated patients with nosocomial pneumonia. Antimicrob Agents Chemother 2011; 55:1606-10.
13. Drusano GL, Preston SL, Gottfried MH, Danziger LH, Rodvold KA. Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother 2002; 46:586-9.
14. Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 1995; 47:331-85.
15. Deziel M, Heine H, Louie A, et al. Identification of effective antimicrobial regimens for use in humans for the therapy of Bacillus anthracis infections and post-exposure prophylaxis. Antimicrob Agents Chemo-ther 2005; 49:5099-106.